Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy Ulrich R. Müller, MD, Marek Jutel, MD,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

In situ imaging of honeybee (Apis mellifera) venom components from aqueous and aluminum hydroxide–adsorbed venom immunotherapy preparations Ulla Seppälä,

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen- specific T-cell tolerance in human tonsils and peripheral blood

Allergen immunotherapy: A practice parameter third update

Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2 Natalija Novak, MD, Nihal Mete, MD, Caroline.

Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus.

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Russell S. Traister, MD, PhD, Crystal E. Uvalle, BS, Gregory A

Advances in food allergy in 2015

Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance Margot Berings, MD, Cagatay Karaaslan,

Impaired TH17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Atopic dermatitis: Age and race do matter!

Erika Lerch, MD, Ulrich R. Müller, MD

The Editors' Choice Journal of Allergy and Clinical Immunology

T-cell regulation during viral and nonviral asthma exacerbations

Is 9 more than 2 also in allergic airway inflammation?

Joe K. Gerald, MD, PhD, Roni Grad, MD, William C. Bailey, MD, Lynn B

Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen- specific T-cell tolerance in human tonsils and peripheral blood

Histamine in the immune regulation of allergic inflammation

T-cell regulation in chronic paranasal sinus disease

Staphylococcus aureus enhances the tight junction barrier integrity in healthy nasal tissue, but not in nasal polyps Can Altunbulakli, MSc, Rita Costa,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

The Editors' Choice Journal of Allergy and Clinical Immunology

Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus.

Physician needs in health informatics: Just ask the docs

Targeting Fel d 1 to FcγRI induces a novel variation of the TH2 response in subjects with cat allergy Kathryn E. Hulse, BS, Amanda J. Reefer, MS, Victor.

Elina Jerschow, MD, MSc, Robert Y. Lin, MD, MSc, Moira M

Peter M. Wolfgram, MD, David B. Allen, MD

The future of allergy/immunology: Promising young investigators

Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis Yuichi Teraki, MD, Misaki Kawabe, MD, Seiichi.

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

News & Notes Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, David Golden, MD

Histamine receptor 2 is a key influence in immune responses to intestinal histamine- secreting microbes Ruth Ferstl, PhD, Remo Frei, PhD, Elisa Schiavi,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Cephalosporin Side Chain Cross-reactivity

Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD

Enhanced CD46-induced regulatory T cells suppress allergic inflammation after Dermatophagoides pteronyssinus–specific immunotherapy Yi-Giien Tsai, MD,

Direct ex vivo analysis of allergen-specific CD4+ T cells

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Lei Wang, MD, PhD, Jesse P. Joad, MD, Caiyun Zhong, MD, PhD, Kent E

A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy Fatimah Kussebi, MD, Fariba Karamloo, PhD, Claudio Rhyner,

Geographic variability in childhood asthma prevalence in Chicago

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Wasp venom immunotherapy expands a subpopulation of CD4+CD25+ forkhead box protein 3–positive regulatory T cells expressing the T-cell receptor Vβ2 and.

IL-10–producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients Antje Prasse, MD, Martin Germann,

Macrolide antibiotics and asthma treatment

The Editors' Choice Journal of Allergy and Clinical Immunology

Asthma: The past, future, environment, and costs

Julie Negri, BA, S. Brandon Early, BA, John W

Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production Monika Majewska-Szczepanik, PhD,

IgG4 production is confined to human IL-10–producing regulatory B cells that suppress antigen-specific immune responses Willem van de Veen, MSc, Barbara.

Environmental factors and eosinophilic esophagitis

Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients Paulina Wawrzyniak, MSc, Marcin.

Natural history of cow’s milk allergy

The Editors’ Choice Journal of Allergy and Clinical Immunology

Primary prevention of asthma and allergy

Presentation transcript:

Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy Ulrich R. Müller, MD, Marek Jutel, MD, Andrea Reimers, MD, Judith Zumkehr, Sci Tec, Clarissa Huber, MD, Carola Kriegel, MD, Urs Steiner, MD, Gabrielle Haeberli, MD, Mübeccel Akdis, MD, PhD, Arthur Helbling, MD, Benno Schnyder, MD, Kurt Blaser, PhD, Cezmi Akdis, MD Journal of Allergy and Clinical Immunology Volume 122, Issue 5, Pages 1001-1007.e4 (November 2008) DOI: 10.1016/j.jaci.2008.08.007 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 BV sIgE and sIgG antibodies and PLA-stimulated proliferation of PBMCs during ultrarush BVIT. A, sIgE levels did not change significantly, although there was a highly significant increase of sIgG levels in both groups. B, PLA-stimulated proliferation decreased in both groups, but the reduction reached significance only in the LC group on day 110. P, Placebo. Journal of Allergy and Clinical Immunology 2008 122, 1001-1007.e4DOI: (10.1016/j.jaci.2008.08.007) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Cytokine secretion in PLA-stimulated PBMC cultures during BVIT. A, IFN-γ levels decreased significantly more in the placebo group on day 21. B, IL-13 levels decreased in both groups between before BVIT and day 110 but significantly more in the placebo group. C, IL-10 levels increased significantly on day 21 compared with those before BVIT in the LC group. P, Placebo. Journal of Allergy and Clinical Immunology 2008 122, 1001-1007.e4DOI: (10.1016/j.jaci.2008.08.007) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Effect of BVIT on HR expression in PLA-stimulated T cells. A, HR1 mRNA expression. B, HR2 mRNA expression. C, HR1/HR2 mRNA expression ratio. Although no significant difference in HR1 and HR2 expression is observed between groups, the HR1/HR2 ratio is significantly lower in the placebo group on day 21. P, Placebo. Journal of Allergy and Clinical Immunology 2008 122, 1001-1007.e4DOI: (10.1016/j.jaci.2008.08.007) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions